Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554074 | 1.00 | HDAC1 (0.52) | HDAC1HDAC2HDAC3HPGDSLTA4H | |
| SCHEMBL5783465 | 0.82 | HDAC1 (0.57) | HDAC1HDAC2HDAC3HPGDSLTA4H | |
| SCHEMBL7609597 | 0.81 | PPARG (0.58) | HDAC1HPGDSLTA4HHDAC6PPARG | |
| SCHEMBL6170897 | 0.81 | PPARG (0.58) | HDAC1HPGDSLTA4HHDAC6PPARG | |
| SCHEMBL12377253 | 0.81 | CTSC (0.59) | CTSC | |
| SCHEMBL18554025 | 0.81 | CTSC (0.59) | CTSC | |
| Hydrochloric Acid SCHEMBL6165154 | 0.81 | HDAC1 (0.56) | HDAC1HDAC2HDAC3HPGDSLTA4H | |
| Hydrochloric Acid SCHEMBL7309860 | 0.80 | PPARG (0.56) | HPGDSLTA4HPPARGPPARA | |
| Hydrochloric Acid SCHEMBL7309851 | 0.80 | PPARG (0.56) | HPGDSLTA4HPPARGPPARA | |
| SCHEMBL6850645 | 0.79 | LTA4H (0.65) | LTA4HPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | claimed |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC | 2020-11-03 | — | — | US | claimed |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2024-12-19 | — | — | US | disclosed |
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC | 2020-11-03 | — | — | US | disclosed |
| US-20180237381-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOL1 | HDAC1 2317/4885HDAC2 2794/4885HDAC3 2059/4885 |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOB | HDAC1 2625/4885HDAC2 3260/4885HDAC3 2514/4885 |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | HDAC1 2625/4885HDAC2 3260/4885HDAC3 2514/4885 |
| US-20180237381-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | HDAC1 2625/4885HDAC2 3260/4885HDAC3 2514/4885 |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | HDAC1 2625/4885HDAC2 3260/4885HDAC3 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.